Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy
- 1 April 1993
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 17 (4), 599-604
- https://doi.org/10.1002/hep.1840170412
Abstract
Serum bile acid levels and distributions were studied every 6 mo in patients with primary biliary cirrhosis who were randomly assigned to receive ursodeoxycholic acid (13 to 15 mg/kg/day) (n = 73) or a placebo (n = 73) over a 2-yr period. In the ursodeoxycholic acid group, ursodeoxycholic acid was the predominant serum bile acid at 6 mo and throughout the 2-yr treatment period. The total concentration of endogenous bile acids decreased with a reduction in cholic acid (in the ursodeoxycholic acid group and the placebo group, respectively [mean :± S.E.]: 13.0 ± 2.2 and 12.6 ± 2.5 μmol/L at entry vs. 3.5 ± 0.6 and 9.0 ± 2.2 μmol/L at 2 yr; p < 0.002), chenodeoxycholic acid (in the ursodeoxycholic acid group and the placebo group, respectively: 12.1 ± 1.7 and 12.7 ± 2.3 μmol/L at entry vs. 5.8 ± 0.8 and 10.7 ± 2.2 μmol/L at 2 yr; p < 0.02) and 3β-hydroxy-δ5-cholenoic acid. The concentration of deoxycholic acid did not change, whereas that of lithocholic acid increased significantly (in the ursodeoxycholic acid group and the placebo group, respectively: 0.63 ± 0.06 and 0.81 ± 0.12 μmol/L at entry vs. 1.26 ± 0.12 and 0.90 ± 0.15 μmol/L at 2 yr; p < 0.001). These changes were independent of the histological stage of the disease. Thus during ursodeoxycholic acid administration the liver was exposed to a lower level of endogenous bile acids and to an increased concentration of ursodeoxycholic acid. These changes in circulating bile acids and their beneficial effects could be explained by the following mechanisms: (a) initially, ursodeoxycholic acid would directly increase hepatocyte excretion of bile acids; (b) their return to the liver would then be limited by an inhibitory effect of ursodeoxycholic acid on their intestinal reabsorption; and (c) liver cell metabolism and functions would be improved by the sustained reduction in the concentration of endogenous bile acids and the predominant presence of ursodeoxycholic acid. (Hepatology 1993;17:599-604.)This publication has 32 references indexed in Scilit:
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisNew England Journal of Medicine, 1991
- Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in manHepatology, 1990
- Ursodeoxycholic acid for the treatment of primary biliary cirrhosisJournal of Hepatology, 1990
- Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acidsGastroenterology, 1990
- Comparative Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on Bile Acid Kinetics and Biliary Lipid Secretion in HumansGastroenterology, 1983
- Serum bile acid analysisClinica Chimica Acta; International Journal of Clinical Chemistry, 1983
- A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phase octadecylsilane bonded silica cartridgesClinica Chimica Acta; International Journal of Clinical Chemistry, 1982
- Synthesis of the specific monosulfates of cholic acidSteroids, 1975
- Quantitative estimation of bile salts in serumCanadian Journal of Biochemistry, 1970
- A modified gas-liquid chromatographic procedure for the rapid determination of bile acids in biological fluidsAnalytical Biochemistry, 1969